TY - JOUR
T1 - Association of cardiac biomarkers with acute kidney injury after cardiac surgery
T2 - A multicenter cohort study
AU - TRIBE-AKI Consortium
AU - Belley-Côté, Emilie P.
AU - Parikh, Chirag R.
AU - Shortt, Colleen R.
AU - Coca, Steven G.
AU - Garg, Amit X.
AU - Eikelboom, John W.
AU - Kavsak, Peter
AU - McArthur, Eric
AU - Thiessen-Philbrook, Heather
AU - Whitlock, Richard P.
AU - Devarajan, Prasad
AU - Edelstein, Charles
AU - Passik, Cary
AU - Swaminathan, Madhav
AU - Patel, Uptal
AU - Zappitelli, Michael
AU - Butrymowicz, Isabel
N1 - Funding Information:
C.R.P. is a consultant for Cardiorentis and AbbVie, and a scientific advisor for Thrasos. A.X.G. has received research funding from Astellas, Roche, Fresenius, Ortho-Biotech, and Pfizer Canada. J.W.E. reports grants and personal fees from Bayer, Boehringer-Ingelheim, AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Pfizer, Janssen, and Sanofi-Aventis, and personal fees from Daiichi Sankyo and Eli Lilly. P.K. has obtained grants/honorarium/advisory or consultant fees from Abbott Laboratories, Abbott Point of Care, Beckman Coulter, Ortho Clinical Diagnostics, Roche Diagnostics, and the Canadian Agency for Drugs and Technologies in Health. All other authors have nothing to disclose with regard to commercial support.
Funding Information:
This study was supported by the Institute for Clinical Evaluative Sciences, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care . The opinions, results, and conclusions reported in this article are those of the authors and are independent from the funding sources. No endorsement by the Institute for Clinical Evaluative Sciences or the Ontario Ministry of Health and Long-Term Care is intended or should be inferred. The Evidence Investigator Cytokine Custom Array 4 kits were donated by Randox Laboratories Ltd. The granting agency, Randox Laboratories Ltd, did not participate in the design and conduct of the study, collection, management, analysis, and interpretation of the data, and preparation, review, or approval of the manuscript. This study was supported by the National Institutes of Health (NIH) ( R01HL085757 to C.R.P.) to fund the TRIBE-AKI Consortium to study novel biomarkers of AKI in cardiac surgery. Biomarker assays were provided in kind by Beckman Coulter and Roche Diagnostics. C.R.P. is supported by the NIH ( K24DK090203 ) and P30 DK079310-07 O'Brien Center Grant. S.G.C. has been supported by an NIH Career Development Award (K23DK080132). C.R.P., S.G.C., and A.X.G. are members of the NIH-sponsored Assess, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury Consortium (U01DK082185).
Funding Information:
This study was supported by the National Institutes of Health (NIH) (R01HL085757 to C.R.P.) to fund the TRIBE-AKI Consortium to study novel biomarkers of AKI in cardiac surgery. Biomarker assays were provided in kind by Beckman Coulter and Roche Diagnostics. C.R.P. is supported by the NIH (K24DK090203) and P30 DK079310-07 O'Brien Center Grant. S.G.C. has been supported by an NIH Career Development Award (K23DK080132). C.R.P., S.G.C., and A.X.G. are members of the NIHsponsored Assess, Serial Evaluation, and Subsequent Sequelae in Acute Kidney Injury Consortium (U01DK082185).
Publisher Copyright:
© 2016 The American Association for Thoracic Surgery.
PY - 2016/7/1
Y1 - 2016/7/1
N2 - Objective Acute kidney injury is common after cardiac surgery and associated with postoperative mortality. Perioperative cardiac biomarkers may predict acute kidney injury and mortality. We evaluated whether cardiac biomarkers were associated with severe acute kidney injury, defined as a doubling in serum creatinine or requiring renal replacement therapy during hospital stay after surgery, and mortality. Methods In a prospective multicenter cohort of adults undergoing cardiac surgery, we measured the following biomarkers in preoperative and postoperative banked plasma: High-sensitivity troponin T, cardiac troponin I, creatine kinase-MB, and N-terminal prohormone of brain natriuretic peptide. Results In the patients who were discharged alive, severe acute kidney injury occurred in 37 of 960 (3.9%), and 43 of 960 (4.5%) died within 1 year of follow-up. N-terminal prohormone of brain natriuretic peptide was the only preoperative biomarker that was independently associated with severe acute kidney injury (with log transformation, adjusted odds ratio, 1.4; 95% confidence interval, 1.0-1.9). Biomarkers measured within 6 hours of surgery (day 1) were all associated with severe acute kidney injury. Preoperative N-terminal prohormone of brain natriuretic peptide was also independently associated with 1-year mortality (with log transformation, adjusted odds ratio, 1.7; 95% confidence interval, 1.2-2.2). Patients in the highest tertile for N-terminal prohormone of brain natriuretic peptide preoperatively (>1006.4 ng/L) had marked increases in their risk for 1-year mortality (adjusted odds ratio, 27.2; 95% confidence interval, 3.5-213.5). Day 1 N-terminal prohormone of brain natriuretic peptide was associated with mortality independently of change in serum creatinine from preoperative baseline. Conclusions Of the studied biomarkers, N-terminal prohormone of brain natriuretic peptide was the only preoperative biomarker independently associated with severe acute kidney injury and mortality. Early increases in postoperative cardiac biomarkers were associated with severe acute kidney injury after cardiac surgery. Future research should focus on whether interventions that lower N-terminal prohormone of brain natriuretic peptide can affect postoperative outcomes.
AB - Objective Acute kidney injury is common after cardiac surgery and associated with postoperative mortality. Perioperative cardiac biomarkers may predict acute kidney injury and mortality. We evaluated whether cardiac biomarkers were associated with severe acute kidney injury, defined as a doubling in serum creatinine or requiring renal replacement therapy during hospital stay after surgery, and mortality. Methods In a prospective multicenter cohort of adults undergoing cardiac surgery, we measured the following biomarkers in preoperative and postoperative banked plasma: High-sensitivity troponin T, cardiac troponin I, creatine kinase-MB, and N-terminal prohormone of brain natriuretic peptide. Results In the patients who were discharged alive, severe acute kidney injury occurred in 37 of 960 (3.9%), and 43 of 960 (4.5%) died within 1 year of follow-up. N-terminal prohormone of brain natriuretic peptide was the only preoperative biomarker that was independently associated with severe acute kidney injury (with log transformation, adjusted odds ratio, 1.4; 95% confidence interval, 1.0-1.9). Biomarkers measured within 6 hours of surgery (day 1) were all associated with severe acute kidney injury. Preoperative N-terminal prohormone of brain natriuretic peptide was also independently associated with 1-year mortality (with log transformation, adjusted odds ratio, 1.7; 95% confidence interval, 1.2-2.2). Patients in the highest tertile for N-terminal prohormone of brain natriuretic peptide preoperatively (>1006.4 ng/L) had marked increases in their risk for 1-year mortality (adjusted odds ratio, 27.2; 95% confidence interval, 3.5-213.5). Day 1 N-terminal prohormone of brain natriuretic peptide was associated with mortality independently of change in serum creatinine from preoperative baseline. Conclusions Of the studied biomarkers, N-terminal prohormone of brain natriuretic peptide was the only preoperative biomarker independently associated with severe acute kidney injury and mortality. Early increases in postoperative cardiac biomarkers were associated with severe acute kidney injury after cardiac surgery. Future research should focus on whether interventions that lower N-terminal prohormone of brain natriuretic peptide can affect postoperative outcomes.
KW - acute kidney injury
KW - biomarkers
KW - brain natriuretic peptide
KW - cardiac surgery
KW - mortality
KW - troponin
UR - http://www.scopus.com/inward/record.url?scp=84961937850&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84961937850&partnerID=8YFLogxK
U2 - 10.1016/j.jtcvs.2016.02.029
DO - 10.1016/j.jtcvs.2016.02.029
M3 - Article
C2 - 27045042
AN - SCOPUS:84961937850
SN - 0022-5223
VL - 152
SP - 245-251.e4
JO - Journal of Thoracic and Cardiovascular Surgery
JF - Journal of Thoracic and Cardiovascular Surgery
IS - 1
ER -